Description

(4R,9As)-4-(3,4,5-Trifluorophenyl)Hexahydropyrido[2,1-C][1,4]Oxazin-6(1H)-One is a high-purity, advanced pharmaceutical intermediate characterized by its complex heterocyclic structure. This compound is of significant value for its role as a key chiral building block in the synthesis of novel active pharmaceutical ingredients (APIs). It is primarily required by research and development organizations and production facilities in the pharmaceutical and fine chemical industries focused on developing new therapeutic agents.

Application

• Pharmaceutical Intermediate: A critical chiral synthon in the research and commercial synthesis of proprietary drug candidates, particularly in central nervous system (CNS) and other therapeutic areas.
• Organic Synthesis Building Block: Used in medicinal chemistry for constructing complex molecular architectures, leveraging its hexahydropyridooxazinone core and trifluorophenyl moiety.
• Process Chemistry & Scale-Up: Serves as a key material for process development, optimization, and pilot-to-commercial scale manufacturing of target molecules.
• Research & Development: Essential for academic and industrial R&D labs exploring new chemical entities, structure-activity relationships (SAR), and novel synthetic pathways.
• Reference Standard: Can be supplied as a high-purity analytical standard for method development, quality control, and regulatory submissions.

Basic Information

Product Name	(4R,9As)-4-(3,4,5-Trifluorophenyl)Hexahydropyrido[2,1-C][1,4]Oxazin-6(1H)-One
CAS No.	937816-17-6
Molecular Formula	C17H15F3N2O2
Molecular Weight	336.31 g/mol
Synonyms	(4R,9aS)-4-(3,4,5-Trifluorophenyl)octahydro-2H-pyrido[2,1-c][1,4]oxazin-6-one; Hexahydropyrido[2,1-c][1,4]oxazin-6(1H)-one, 4-(3,4,5-trifluorophenyl)-, (4R,9aS)-; (4R,9aS)-4-(3,4,5-Trifluorophenyl)-1,2,3,4,9,9a-hexahydro-6H-pyrido[2,1-c][1,4]oxazin-6-one; CAS 937816-17-6; 937816-17-6.
EINECS	Contact for details

Quality Control

Our (4R,9As)-4-(3,4,5-Trifluorophenyl)Hexahydropyrido[2,1-C][1,4]Oxazin-6(1H)-One is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and consistency, meeting the stringent requirements for pharmaceutical intermediates. Certificates of Analysis (COA) detailing purity, chiral purity, and impurity profiles are provided with every shipment. We support compliance with cGMP, ICH Q7, and relevant pharmacopeial standards as required.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). Due to its hygroscopic nature, the container must be kept tightly sealed under dry, inert conditions to prevent moisture absorption and degradation. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Chiral Purity (Chiral HPLC)	≥ 99.0% ee
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single unknown impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.